A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Brief description of study

The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment for advanced or metastatic solid tumors with a proven ALK, ROS or NTRK 1-3 gene rearrangement. An investigational medication or drug is one that has not been approved by the U.S. Food & Drug Administration (FDA).

Clinical Study Identifier: s19-00440
ClinicalTrials.gov Identifier: NCT03093116
Principal Investigator: Vamsidhar Velcheti.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.